Trials / Completed
CompletedNCT02301130
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mogamulizumab | Mogamulizumab will be administered intravenously (IV). |
| BIOLOGICAL | MEDI4736 (Durvalumab) | MEDI4736 will be administered intravenously (IV). |
| BIOLOGICAL | tremelimumab | Tremelimumab will be administered intravenously (IV). |
Timeline
- Start date
- 2014-11-26
- Primary completion
- 2017-12-08
- Completion
- 2018-03-05
- First posted
- 2014-11-25
- Last updated
- 2024-04-25
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02301130. Inclusion in this directory is not an endorsement.